Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism ‐related factors in patients with type‐2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial

Diabetes, Obesity and Metabolism,Volume 0, Issue ja, -Not available-.

Source: Diabetes, Obesity and Metabolism - October 12, 2018 Category: Endocrinology Authors: Kyu Yon1g Cho, Akinobu Nakamura, Kazuno Omori, Takahiro Takase, Aika Miya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi Source Type: research